Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings results on Monday. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.05, Briefing.com reports.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded down 5.34% during trading on Tuesday, hitting $14.72. The stock had a trading volume of 47,846 shares. The stock has a 50 day moving average of $14.69 and a 200 day moving average of $15.88. The firm’s market cap is $428.48 million. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $25.73.

In other news, EVP Gad Soffer sold 12,674 shares of the stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $15.16, for a total transaction of $192,137.84. Following the sale, the executive vice president now owns 259,527 shares in the company, valued at $3,934,429.32. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total transaction of $75,900.00. Following the sale, the executive vice president now owns 368,080 shares in the company, valued at approximately $4,656,212. The disclosure for this sale can be found here. Insiders have sold 54,308 shares of company stock valued at $797,382 in the last ninety days. Insiders own 16.10% of the company’s stock.

ATRA has been the subject of a number of analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price target on shares of Atara Biotherapeutics in a research note on Friday, April 21st. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Finally, ValuEngine downgraded Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Three research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $25.75.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/atara-biotherapeutics-inc-atra-issues-earnings-results.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.